Repaglinide in the management of new-onset diabetes mellitus after renal transplantation.
The purpose of this study was to investigate the use of the short-acting insulin secretion drug repaglinide in new-onset diabetes mellitus (NODM) after renal transplantation. Twenty-three Caucasian patients with NODM after renal transplantation were selected to receive repaglinide therapy and were followed for at least 6 months. A control group treated with rosiglitazone was chosen for comparison. Successful repaglinide treatment was defined as a significant improvement of blood glucose concentrations and HbA1c <7% in the absence of glucosuria and without the need for the addition of further anti-diabetic agents. After 6 months of treatment with repaglinide, 14 of the 23 patients were successfully treated. Mean HbA1c decreased from 7.6 +/- 0.6% to 5.8 +/- 0.6% in 14 patients treated successfully. In nine patients, hyperglycemia persisted, and they were switched to insulin treatment (HbA1c 8.5 +/- 2.9% at the beginning to 7.4 +/- 2.2%). Mean serum creatinine levels, cyclosporine A and tacrolimus blood levels did not change significantly following institution of repaglinide therapy. The rate of successful treatment and the degree of HbA1c decrease were similar compared to rosiglitazone-treated control patients. The data from our observational study indicate that repaglinide can be an effective treatment option in Caucasian patients with NODM after renal transplantation.
Türk
T
T
Department of Nephrology and Hypertension, School of Medicine, University of Diusburg-Essen, Hufelandstrasse 55, D-45122 Essen, Germany.
Pietruck
F
F
Dolff
S
S
Kribben
A
A
Janssen
O E
OE
Mann
K
K
Philipp
T
T
Heemann
U
U
Witzke
O
O
D002219:Carbamates / Q000627:therapeutic use*; D003920:Diabetes Mellitus / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D010880:Piperidines / Q000627:therapeutic use*; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000627:therapeutic use; D016896:Treatment Outcome
D002219:Carbamates; D007004:Hypoglycemic Agents; D010880:Piperidines; D045162:Thiazolidinediones; D000077154:Rosiglitazone; C072379:repaglinide